Breaking News

Nomura, MUFJ-MS, Goldman, JPMorgan to Lead Japan Post IPO
Tweet TWEET

WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional

     WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody
    Development and Commercial Opportunities for Asian Regional and Global
                           Pharmaceutical Companies

PR Newswire

SHANGHAI and PALO ALTO, Calif., March 5, 2013

SHANGHAI and PALO ALTO, Calif., March 5, 2013 /PRNewswire/ --WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical
device R&D outsourcing company with operations in China and the United States,
and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic
animals for development of human therapeutic antibodies, today announced a
second agreement to expand WuXi's use of OMT's OmniRat™ and OmniMouse™
technologies to strengthen the development and commercial opportunities for
WuXi's Asian regional and global clients.

The OmniRat platform has now been duplicated at WuXi's Shanghai facility,
enabling WuXi to generate antibodies for customers from its own laboratories.
WuXi is the first and currently the only company authorized by OMT to host
OmniRat in China. This transaction advances WuXi's goal of working with
skilled partners to enhance the company's technologies and capabilities to
better serve its customers.

Under the new agreement, WuXi's clients can choose to develop and
commercialize products globally or regionally in China, Korea, Japan or other
Asian territories. Clients that opt for regional rights first can assume
global rights prior to the first human dose. This is particularly attractive
for companies that have already established regional Asian operations and have
aspirations to become global later. OMT retains the global product rights
until and unless each option is exercised.

"This new agreement allows WuXi to further expand its service offerings with
the OmniRat and OmniMouse platforms," said Edward Hu, Chief Operating Officer
and Chief Financial Officer of WuXi PharmaTech. "WuXi is proud of the
confidence OMT has shown in the quality of WuXi's antibody research
capabilities and intellectual property protection practices in authorizing
WuXi to host the OmniRat and OmniMouse platforms in our laboratories."

Dr. Roland Buelow, founder and CEO of OMT, continued, "This second agreement
with WuXi continues the global deployment of OMT's human antibody
technologies. The deal structure enables OMT to tap into the economics of
rapidly growing Asian companies and, when global rights are not exercised by
WuXi's clients, to leverage their data for OMT product development and/or
partnering outside Asia."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device
R&D outsourcing company, with operations in China and the United States. As a
research-driven and customer-focused company, WuXi PharmaTech provides
pharmaceutical, biotechnology and medical device companies with a broad and
integrated portfolio of laboratory and manufacturing services throughout the
drug and medical device R&D process. WuXi PharmaTech's services are designed
to help its global partners shorten the cycle and lower the cost of drug and
medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as
WuXi AppTec.

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of
animals for the development of human therapeutic antibodies – "naturally
optimized human antibodies™".

OMT has created OmniRat™, the first fully human monoclonal antibody platform
based on transgenic rats. OMT's genetic engineering is based on an improved
understanding of B cell development and a new approach to inactivation of
endogenous antibody expression, which enables OmniRat to make antibodies with
human idiotypes as efficiently as wild type rats make normal antibodies.
OmniRat represents a novel and proprietary technology with unrestricted
development options for fully human monoclonal antibodies, available worldwide
for all targets and indications.

OMT also develops a transgenic mouse, OmniMouse™, to complement OmniRat and
further increase epitope coverage in human antibody development.

OmniAb™ integrates OMT's transgenic animal platforms, proven protein and DNA
immunization and Gel-Encapsulated Microenvironment (GEM) deep antibody
screening to enable fast and cost-efficient generation and identification of
preferred human therapeutic antibody candidates.

For more information, please visit www.wuxiapptec.com and www.omtinc.net or
contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Phone: +1-201-585-2048
E-mail: Ron_Aldridge@wuxiapptec.com

Brian Lundstrom
Chief Business Officer
Open Monoclonal Technology, Inc.
Phone:+  1-775-420-7750
E-mail: bl@omtinc.net

SOURCE WuXi PharmaTech (Cayman) Inc.

Website: http://www.wuxiapptec.com
Website: http://www.omtinc.net
 
Press spacebar to pause and continue. Press esc to stop.